Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Orphazyme A/S ORPH
$0.87
На 18:03, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
0.00000000
-
week52high
77.77
-
week52low
0.51
-
Revenue
0
-
P/E TTM
0
-
Beta
0.80232000
-
EPS
-3.83400000
-
Last Dividend
0.00000000
-
Next Earnings Date
05 апр 2022 г. в 04:00
Описание компании
Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company focuses on the amplification of heat-shock proteins to develop and commercialize therapeutics for diseases caused by protein misfolding and aggregation, and lysosomal dysfunction, including lysosomal storage and neuromuscular degenerative diseases. Its lead candidate is the Arimoclomol, which is in clinical development for four orphan diseases, including Niemann-Pick disease type C, Amyotrophic Lateral Sclerosis, Inclusion Body Myositis, and Gaucher disease. The company was incorporated in 2009 and is headquartered in Copenhagen, Denmark.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| B of A Securities | Underperform | Neutral | 30 мар 2021 г. |
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Свежие комментарии
Свежие комментарии